Change in PsAID-12 scores in patients continuing or discontinuing anti-TNF treatments in psoriatic arthritis: results from the HUR-BIO biologic registry
Tarih
2019-01-21Yazar
Kalyoncu, Umut
Kiraz, Sedat
Apras Bilgen, Sule
Karadağ, Ömer
Akdoğan, Ali
Kılıç, Levent
Erden, Abdulsamet
Armagan, Berkan
Sari, Alper
Ertenli, İhsan
- Citations
- CrossRef - Citation Indexes: 6
- PubMed - Citation Indexes: 3
- Scopus - Citation Indexes: 8
- Captures
- Mendeley - Readers: 22
publications
0
supporting
0
mentioning
0
contrasting
0
0
0
0
0
Citing PublicationsSupportingMentioningContrasting
See how this article has been cited at scite.ai
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Üst veri
Tüm öğe kaydını gösterÖzet
Objective
Psoriatic Arthritis Impact of Disease 12-item questionnaire (PsAID-12) has been developed to be used in psoriatic arthritis in daily practice. The aim of the present study was to assess the change values of PsAID-12 in PsA patients continuing or discontinuing anti-TNF treatment.
Methods
We recruited patients from the Hacettepe University biological database (HUR-BIO). Overall, 70 PsA patients had PsAID-12 score before the initiation of the first anti-TNF treatment. Stopping or switching the anti-TNF treatment due to inefficacy was definitely considered a negative response. Changes were evaluated by the comparison with the baseline PsAID-12 score in compliance with the favorable and unfavorable responses to anti-TNF treatments. The standardized response mean (SRM) was used for determining the response.
Results
Seventy (78.6% female) patients were analyzed and their mean age was 45.5 years (12.0 years). The mean follow-up duration was 18.3 months (12.6 months). At baseline, the mean PsAID-12 score was 6.6 (1.5). Physicians stopped or switched the treatment in 28 patients (40.0%) due to the inefficacy of anti-TNF treatment. The ΔPsAID-12 score was 0.25 (1.71) in the patients discontinuing anti-TNF treatment and 3.52 (2.31) in the patients continuing their anti-TNF treatment (p < 0.001). The SRM scores higher for PsAID-12, particularly in the well response to anti-TNF treatments.
Conclusion
A decrease of 3.5 units in PsAID-12 score shows a favorable response to anti-TNF treatment. Changes in PsAID-12 score had well discrimination capacity for anti-TNF treatments.
Bağlantı
http://hdl.handle.net/11655/23566https://doi.org/10.1007/s10067-019-04426-3
https://pubmed.ncbi.nlm.nih.gov/30663017/
Koleksiyonlar
Künye
Kalyoncu U, Kiraz S, Bilgen SA, Karadag O, Akdogan A, Kilic L, Erden A, Armagan B, Sari A, Ertenli I. Change in PsAID-12 scores in patients continuing or discontinuing anti-TNF treatments in psoriatic arthritis: results from the HUR-BIO biologic registry. Clin Rheumatol. 2019 Apr;38(4):1187-1192. doi: 10.1007/s10067-019-04426-3. Epub 2019 Jan 21. PMID: 30663017.Aşağıdaki lisans dosyası bu öğe ile ilişkilidir: